Russell Investments Group
CUE icon

Russell Investments Group’s Cue Biopharma CUE Stock Holding History

Russell Investments Group’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6
Closed -$454 – 3320
2023
Q4 		$454 Buy
6
+2
+50% +$143 ﹤0.01% 3129
2023
Q3 		$278 Buy
+4
New +$391 ﹤0.01% 3453
2022
Q2 		– Sell
-40
Closed -$5K – 2900
2022
Q1 		$5K Hold
40
– – ﹤0.01% 2727
2021
Q4 		$13K Hold
40
– – ﹤0.01% 2971
2021
Q3 		$17K Sell
40
-2,045
-98% -$713K ﹤0.01% 3000
2021
Q2 		$728K Buy
2,085
+1,171
+128% +$454K ﹤0.01% 2449
2021
Q1 		$333K Sell
914
-783
-46% -$322K ﹤0.01% 2673
2020
Q4 		$636K Buy
1,697
+592
+54% +$237K ﹤0.01% 2330
2020
Q3 		$498K Hold
1,105
– – ﹤0.01% 2398
2020
Q2 		$809K Sell
1,105
-550
-33% -$398K ﹤0.01% 2168
2020
Q1 		$701K Sell
1,655
-86
-5% -$41.7K ﹤0.01% 2014
2019
Q4 		$828K Buy
1,741
+1,476
+557% +$464K ﹤0.01% 2205
2019
Q3 		$67K Buy
+265
New +$63.7K ﹤0.01% 2900

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Russell Investments Group's CUE Position: Q1 2024 in Review

Russell Investments Group sold out of Cue Biopharma (CUE) in Q1 2024, closing a stake of 6 shares — an estimated $454 sold.

Russell Investments Group first reported a position in CUE in Q3 2019 and held it in 13 quarters. The position peaked at $828K in Q4 2019. 74 funds tracked by Wall St. Rank hold CUE as of Q1 2024.

  • Russell Investments Group reported no remaining Cue Biopharma position as of Q1 2024 after selling out during the quarter.
  • Russell Investments Group sold 6 Cue Biopharma shares in Q1 2024, an estimated $454.
  • Russell Investments Group first reported a position in Cue Biopharma in Q3 2019 and held it in 13 quarters.
  • Russell Investments Group's Cue Biopharma position peaked at $828K in Q4 2019.
  • 74 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2024.

Based on Russell Investments Group's 13F filing for Q1 2024, filed 8 May 2024.